ProCE Banner Activity

CE

Tailoring Treatment of EGFR-Mutated NSCLC: Pharmacy Perspectives to Improve Patient Care

Multimedia
In this on-demand CPE-certified Webcast of a CCO symposium at HOPA 2018, Val R. Adams, PharmD, FCCP, BCOP; Philip Schwieterman, PharmD, MHA; and H. Jack West, MD, review and discuss the latest data on EGFR-targeted therapies for advanced EGFR-mutated NSCLC as they apply to pharmacists.

Pharmacists : 1.50 contact {hours} ({0.15} CEUs)

Released: April 23, 2018

Expiration: April 22, 2019

No longer available for credit.

Share

Faculty

Val R. Adams

Val R. Adams, PharmD, FCCP, BCOP

Associate Professor
Department of Pharmacy Practice and Science
University of Kentucky
Lexington, Kentucky

Philip Schwieterman

Philip Schwieterman, PharmD, MHA

Director of Oncology and Pediatric Pharmacy
Markey Cancer Center
UK Health Care
Lexington, Kentucky

H. Jack West

H. Jack West, MD

Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
Seattle, Washington

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca

Target Audience

This program is intended for pharmacists, managed care professionals, and healthcare providers who care for patients with non-small-cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Examine current recommendations for molecular testing and the roles for liquid biopsies in guiding therapy, especially as it relates to EGFR T790M mutations
  • Compare current and emerging frontline treatment strategies for advanced EGFR-mutated NSCLC focusing on safety, efficacy, and the individualization of therapy based on tumor-specific and patient-specific factors
  • Evaluate current and evolving treatment approaches to address acquired resistance and progression in advanced EGFR-mutated NSCLC
  • Discuss the roles of oncology and managed care pharmacists in optimizing the use of targeted therapy in advanced EGFR-mutated NSCLC, managing therapy-related toxicities, improving adherence, educating patients, and aiding in the implementation of clinical pathways to deliver quality care

Program Director Disclosure

Program Director

Val R. Adams, PharmD, FCCP, BCOP

Associate Professor
Department of Pharmacy Practice and Science
University of Kentucky
Lexington, Kentucky

Val R. Adams, PharmD, FCCP, BCOP, has no real or apparent conflicts of interest to report.

Faculty Disclosure

Primary Author

Philip Schwieterman, PharmD, MHA

Director of Oncology and Pediatric Pharmacy
Markey Cancer Center
UK Health Care
Lexington, Kentucky

Philip Schwieterman, PharmD, MHA, has no real or apparent conflicts of interest to report.

H. Jack West, MD

Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
Seattle, Washington

H. Jack West, MD, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, and Genentech/Roche and fees for non-CME/CE services from Genentech/Roche.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright has no real or apparent conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit


Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-9999-18-084-H01-P

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 23, 2018, through April 22, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to educate pharmacists and managed care professionals about advances in the clinical management of patients with EGFR-mutated non-small-cell lung cancer.